ArticleFrontiers in aging neuroscience2025
Gamma-aminobutyric acid associated research in Parkinson's disease: an exploratory trends analysis.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the Gut-Brain-Ferroptosis Axis: Molecular Mechanisms and Therapeutic Potential in Alzheimer's Disease and Epilepsy.Journal of molecular neuroscience : MN · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a neurodegenerative disease characterized by the progressive loss of dopaminergic neurons. Gamma-aminobutyric acid (GABA), as a key inhibitory neurotransmitter, participates in physiological processes such as cognition and motor control by regulating the balance of neuronal excitability. Related studies have found that the GABAergic signaling abnormalities in the basal ganglia and thalamocortical circuits are closely associated with the motor dysfunction and non-motor symptoms of PD. This study aimed to analyze GABA and PD research literature to further identify hotspots, frontiers, and development directions. Method: Data were obtained from the Web of Science, Scopus, and PubMed databases. VOSviewer and CiteSpace were used to visualize and perform quantitative analyses. Results: From 2001 to 2024, a total of 630 publications related to GABA and PD were identified, and the annual publication count fluctuated with an overall upward trend. The United States and China contributed a large number of publications. Karolinska Institute was the leading research institution. Conclusion: This study delineates a comprehensive knowledge structure of GABA and PD research. Enhanced collaboration among authors across institutions and countries is pivotal to advancing the field. The mechanism of GABA in the basal ganglia region is a focus of current research. The detrimental effects of α-synuclein and oxidative stress on the GABAergic system and the non-motor symptom of anxiety are likely to be the frontiers of future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.